All posts by admin

07Aug/13

First Patient Treated with Civacir® after Hepatitis C Induced Liver … – MarketWatch (press release)

First Patient Treated with Civacir® after Hepatitis C Induced Liver
MarketWatch (press release)
Civacir, a 10 % hepatitis C hyperimmune globulin developed and produced at Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG, is being used in a clinical trial in North America in patients undergoing liver transplantation as
Biotest commences phase III trial of hepatitis C therapyZenopa

all 2 news articles »